Progress with ribozymes

Ribozyme Pharmaceuticals Inc. was one of the many companies that went public in the mid-1990s with very early-stage technology. Since then, progress in delivering ribozymes to cells and improvements in their half-life have removed some important hurdles to development of ribozymes as therapeutics.

One result was last week's deal with